BOD SCIENCE LIMITED (BOD)

The audit of the Company's Full Year Accounts for the year ended 30th June 2024 has not yet commenced and is expected to start in early October 2024. The Company now expects that the Appendix 4E and audited Full Year Accounts for the year ended 30th June 2024 will be lodged with the ASX by 31st October 2024.

The Appendix 4E and audited Full Year Accounts for the year ended 30th June 2024 will not be lodged with the ASX by the deadline of 31st August 2024. The audit of the Company's Full Year Accounts for the year ended 30th June 2024 is expected to commence in early September 2024. It is expected that the Appendix 4E and audited Full Year Accounts for the year ended 30th June 2024 will be lodged with the ASX by 30th September 2024.

The company lodges its notice of cessation of securities.

The company lodges its Quarterly Activities/Appendix 4C Cash Flow Report.

The company lodges its Appendix 4D and Half Year Account.

The DOCA will be effectuated once the Conditions Subsequent are satisfied, in particular passing of the various resolutions at an extraordinary general meeting of the Company, which was originally scheduled to be held in or around mid 2024. Due to the delay in executing the Shares Purchase Agreement with Biortica, the DOCA period has been extended and the extraordinary general meeting of the shareholders of the Company is expected to be convened in or around September 2024. The actual date of extraordinary general meeting will be advised in a formal Notice of Meeting, which will be issued in due course.

The securities of the company have been suspended for more than three months. If an entity does not meet the 1 or 2 year deadlines, it will be removed from the official list. The removal will usually take effect from the open of trading on the first trading day after the deadline date.

The half-year review by the Company's auditor Nexia Sydney Audit Pty Ltd is continuing and the Company now expects that the Appendix 4D and Half-Year Report for the half-year ended 31st December 2023 will be lodged with the ASX by 12th July 2024. The Company also expects that the Appendix 4E and Annual Report for the year ending 30th June 2024 will be lodged with the ASX by 31st August 2024 in accordance with the ASX's reporting requirements.

The half-year review by the Company's auditor Nexia Sydney Audit Pty Ltd is close to completion and the Company now expects that the Appendix 4D and Half-Year Report for the half-year ended 31st December 2023 will be lodged with the ASX by 14th June 2024.

The Appendix 4D and Half-Year Report that was supposed to be lodged by 30th April 2024 is still ongoing and the Company now expects that the half-year review will be lodged by 24th May 2024.

The Deed Administrator of the company announce that on 8 April 2024, creditors of BOD resolved to accept a Deed of Company Arrangement as proposed by Biortica Agrimed Limited. The DOCA was executed on 24 April 2024.

The company releases the quarterly activities report.

The Administrators have today issued their report to creditors and their notice to convene the second meeting of creditors which will be held on 8 April 2024.

The Company was advised by ASIC on 22nd March 2024 that it had rejected the application of Bod's incumbent auditor, Nexia Sydney Audit Pty Ltd, to resign as the Company's auditor due to a perceived conflict of interest. Due to delays in receiving the ASIC decision, the Company's half-year review by Nexia Sydney Audit Pty Ltd has not yet commenced and the Company will not meet the previously advised expected lodgement date of 28th March 2024. The Company now expects that the Appendix 4D and Half-Year Report for the half-year ended 31st December 2023 will be lodged with the ASX by 30th April 2024.

The Company was advised by ASIC on 22nd March 2024 that it had rejected the application of Bod's incumbent auditor, Nexia Sydney Audit Pty Ltd, to resign as the Company's auditor due to a perceived conflict of interest. Due to delays in receiving the ASIC decision, the Company's half-year review by Nexia Sydney Audit Pty Ltd has not yet commenced and the Company will not meet the previously advised expected lodgement date of 28th March 2024. The Company now expects that the Appendix 4D and Half-Year Report for the half-year ended 31st December 2023 will be lodged with the ASX by 30th April 2024.

The Company's Appendix 4D and Half Year Report for the half-year ended 31st December 2023 will not be lodged by today's deadline. On 20th February 2024, Bod's auditor, Nexia Sydney Audit Pty Ltd, lodged an application with ASIC to resign as the Company's auditor due to a perceived conflict of interest. In.Corp Audit & Assurance Pty Ltd has advised the Company that it is prepared to accept the appointment as auditor to Bod and on 20th February 2024, In.Corp Audit & Assurance Pty Ltd was appointed as the Company's auditor, subject to the consent of ASIC. The Company, former auditor and new auditor are awaiting upon ASIC approval before the review for the half-year ended 31st December 2023 can commence. The ASIC form 342 was lodged with ASIC on 21st February 2024 and a response is expected within two to three weeks of that date. It is expected that the Appendix 4D and Half-Year Report for the half-year ended 31st December 2023 will be lodged with the ASX by 28th March 2024, dependent upon receiving ASIC consent within the expected timeframe.

The company releases a notification of cessation of securities.

The company lodges its Quarterly Activities/Appendix 4C Cash Flow Report.

The Administrators of BOD Science Limited announce that on 14 December 2023, the Federal Court of Australia granted an extension of the period by which the Administrators must convene the second meeting of creditors to no later than 29 March 2024.

Supply agreement with licenced cultivator, importer and genetic holder of medicinal cannabis, Green Farmers Pty Ltd (Licence Number MC022/18v3) (Green Farmers). Green Farmers is a leading Australian grower of medicinal cannabis, with a cropping facility (glasshouse) of 4,000 sqm of cultivation area.

The Company releases a letter to its shareholders regarding the appointment of Administrators. The appointment was made by the Company's directors, who took the step to appoint the Voluntary Administrators to enable them, as experienced and independent parties, to assess the Company's options as to how to secure and sustain the future viability of the business. The Voluntary Administrators are presently considering opportunities to obtain funding from interested parties and/or sell the business. In the meantime, it is business as usual, as far as possible, for the Company in the short term.

On 29 November 2023, the Board of Directors of Bod Science Limited the Board of Directors of Bod Science Limited of Rodgers Reidy as Joint and Several Administrators of the Company pursuant to section 436A of the Corporations Act 2001.

The securities of BOD Science Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of BOD, pending the release of an announcement regarding a potential corporate transaction critical to its continued financial viability.

The suspension of trading in the securities of BOD Science Limited will be lifted immediately following the release by BOD of an announcement regarding its capital raising.

Bod Science has received firm commitments to raise a total of A$2.05 million under a two-tranche placement at an offer price of $0.03 per share. Bod's partner for Malaysia, Antah Healthcare, cornered the raising and will emerge as a 14.9% shareholder. Proceeds will be utilised to fund to fund inventory build, product manufacture, R&D activity to support Aqua Phase and working capital. Post transaction the Company's pro forma cash balance (as at 30 September 2023) will be $2.165m. Cash management initiatives including reduced executive salaries and director fees to be taken in shares (subject to shareholder approval).

The extension to the voluntary suspension is required to enable the Company to finalise its capital raising in an orderly manner. The Company expects the voluntary suspension to last for an additional two trading days. The Company requests that the voluntary suspension remain in place until the earlier of such time as it makes an announcement to the market in relation to the outcome of the capital raising and the commencement of trading on Wednesday, 8 November 2023.

The securities of BOD Science Limited were suspended from quotation under Listing Rule 17.5 on Wednesday, 1 November 2023 as BOD did not lodge its Full Year Statutory Accounts by the due date. BOD has since lodged its Full Year Statutory Accounts, however BOD will continue to be suspended from quotation under Listing Rule 17.2, at the request of BOD, pending the release of an announcement regarding its capital raising.

The securities of the company will be suspended from quotation under Listing Rule 17.5 from the commencement of trading today, Wednesday, 1 November 2023, for not lodging the relevant periodic report by the due date. If the report is lodged between the closure of the market announcements office on Tuesday, 31 October 2023, and the imposition of the suspension, the entity's securities will normally be reinstated to quotation on the next trading day after the suspension is imposed.

name changed from Bod Australia Limited